Re: Stockholm3 Versus Prostate-specific Antigen in Prostate Cancer Screening: 9 yr Outcomes Demonstrating Improved Detection of Aggressive Cancers and Reduced Overdiagnosis from the STHLM3 Trial
Authors:
- Roman GulatiRoman Gulati
- Ruth EtzioniRERuth Etzioni
- 1 October 2026
- journal article
- Published by Elsevier in European Urology
Abstract
No abstract availableFunding Information
- Fred Hutchinson Cancer Center
- National Cancer Institute (R50CA221836)
- National Cancer Institute (U01CA253915)
This publication has 4 references indexed in Scilit:
- Stockholm3 Versus Prostate-specific Antigen in Prostate Cancer Screening: 9-year Outcomes Demonstrating Improved Detection of Aggressive Cancers and Reduced Overdiagnosis from the STHLM3 TrialEuropean Urology, 2025
- Prostate cancer screening in men aged 50–69 years (STHLM3): a prospective population-based diagnostic studyThe Lancet Oncology, 2015
- Biomarker: Predictive or Prognostic?Journal of Clinical Oncology, 2015
- Overdiagnosis and Overtreatment of Prostate CancerEuropean Urology, 2014